Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation.
Tapsi KumarEvthokia A HobbsFei YangJeffrey T ChangAlejandro ContrerasEdwin Roger Parra CuentesHaven R GarberSanghoon LeeYiling LuMarion E ScogginsBeatriz E AdradaGary J WhitmanBanu K ArunElizabeth A MittendorfJennifer K LittonPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
This is the first study with phenotyping to characterize the immune response to neoadjuvant talazoparib in patients with gBRCA1/2+ breast cancer. These findings support an emerging role for PARP inhibitors in enhancing tumor immunogenicity. Further investigation of combinatorial strategies is warranted with agents that exploit the immunomodulatory effects of PARP inhibitors on the TiME.